Stock Market News

Boston Beer amends manufacturing deal, cuts steerage

Investing.com -- Boston Beer Firm Inc (NYSE:SAM) minimize its full-year GAAP earnings per share steerage to $3.80-$5.80, down from $5.50-$7.50.  …

1 month ago

Canada shares larger at shut of commerce; S&P/TSX Composite up 0.76%

Investing.com – Canada shares had been larger after the shut on Friday, as positive factors within the Healthcare, Clear Expertise…

1 month ago

Mexico shares greater at shut of commerce; S&P/BMV IPC up 0.72%

Investing.com – Mexico shares have been greater after the shut on Friday, as positive aspects within the Industrials, Client Items…

1 month ago

U.S. shares increased at shut of commerce; Dow Jones Industrial Common up 1.18%

Investing.com – U.S. shares have been increased after the shut on Friday, as features within the Financials, Utilities and Expertise…

1 month ago

Unique-Nippon Metal alleges undue White Home affect on doomed deal assessment, letter says

By Alexandra Alper WASHINGTON (Reuters) -Nippon Metal alleges the White Home had "impermissible undue affect" over a nationwide safety assessment…

1 month ago

Arm lawsuit ends in mistrial with Qualcomm securing key win

By Tom Hals (Reuters) -Arm Holdings' lawsuit in opposition to Qualcomm (NASDAQ:QCOM) led to a mistrial on Friday, with a…

1 month ago

Lilly’s weight-loss therapy Zepbound turns into first FDA-approved drug for sleep apnea

By Bhanvi Satija (Reuters) -The U.S. Meals and Drug Administration on Friday accredited Eli Lilly (NYSE:LLY)'s weight-loss therapy, Zepbound, for…

1 month ago

Qualcomm scores main authorized victory in opposition to Arm over chip designs

Investing.com -- Qualcomm scored a significant authorized victory on Friday when a U.S. jury decided that the corporate did not…

1 month ago

US authorities shutdown might price journey sector $1 billion per week, disrupt vacation journey

By David Shepardson WASHINGTON (Reuters) - A partial authorities shutdown might price the U.S. journey business $1 billion per week…

1 month ago

Roche’s Parkinson’s drug misses essential aim in mid-stage trial

Investing.com -- Roche's experimental Parkinson's illness drug, prasinezumab, failed to satisfy its main goal in a mid-stage trial. The Swiss…

1 month ago